Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson’s disease

Magnetic Resonance Imaging–Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease

(2019) Chadwick W. Christine et al.   ANNALS OF NEUROLOGY

Inhaling xenon ameliorates l -dopa-induced dyskinesia in experimental parkinsonism

(2018) Jérôme Baufreton et al.   MOVEMENT DISORDERS

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

(2018) Estefania Rojo-Bustamante et al.   NEUROBIOLOGY OF DISEASE

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

(2018) Stéphane Palfi et al.   Human Gene Therapy Clinical Development

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease

(2017) Wai Kin D. Ko et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias

(2017) Jennifer Stanic et al.   NEUROBIOLOGY OF DISEASE

Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques

(2017) Francesco Napolitano et al.   PLoS One

Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease

(2017) Yoshihide Sehara et al.   Human Gene Therapy Clinical Development

Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA–Induced Dyskinesia

(2016) Michel Engeln et al.   BIOLOGICAL PSYCHIATRY

Continuous dopaminergic stimulation therapy for Parkinsonʼs disease – recent advances

(2016) Jonathan Timpka et al.   CURRENT OPINION IN NEUROLOGY

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models

(2016) Wai Kin D. Ko et al.   NEUROPHARMACOLOGY

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

(2015) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

(2015) R.T. Bartus et al.   NEUROBIOLOGY OF DISEASE

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

(2015) Weixing Shen et al.   NEURON

Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease

(2015) Nikhil M. Urs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkey

(2015) Mathieu Bourdenx et al.   SYNAPSE

Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia

(2014) Michel Engeln et al.   CEREBRAL CORTEX

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

(2014) Stéphane Palfi et al.   LANCET

Novel formulations and modes of delivery of levodopa

(2014) Werner Poewe et al.   MOVEMENT DISORDERS

Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections

(2014) Mohammadreza Shariatgorji et al.   NEURON

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia

(2013) Mathieu Bourdenx et al.   NEUROBIOLOGY OF DISEASE

Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease

(2013) Erik Cederfjäll et al.   Scientific Reports

Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease

(2012) Gabriele Mittermeyer et al.   HUMAN GENE THERAPY

PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking

(2012) Gregory Porras et al.   JOURNAL OF CLINICAL INVESTIGATION

Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease

(2012) Erik Cederfjäll et al.   MOLECULAR THERAPY

A critique of available scales and presentation of the non-human primate dyskinesia rating scale

(2012) Susan H. Fox et al.   MOVEMENT DISORDERS

Endogenous morphine-like compound immunoreactivity increases in parkinsonism

(2011) G. Charron et al.   BRAIN

Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson’s disease

(2010) Tomas Björklund et al.   BRAIN

Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC

(2010) Piotr Hadaczek et al.   MOLECULAR THERAPY

Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease

(2010) Sylvia Navailles et al.   NEUROBIOLOGY OF DISEASE

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia

(2010) Emanuela Santini et al.   PLoS One

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

(2010) S. Fasano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lentiviral Overexpression of GRK6 Alleviates L-Dopa-Induced Dyskinesia in Experimental Parkinson's Disease

(2010) M. R. Ahmed et al.   Science Translational Medicine

Optimization of continuousin vivoDOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats

(2009) Tomas Björklund et al.   JOURNAL OF NEUROCHEMISTRY

Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates

(2009) Hemraj B Dodiya et al.   MOLECULAR THERAPY

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

(2009) C. W. Christine et al.   NEUROLOGY

Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia

(2009) B. Jarraya et al.   Science Translational Medicine